Besides the genotype/phenotype associations, the biological mechanisms explaining the impact of SLC6A14 on intestinal and lung phenotypes of CF patients are beginning to be elucidated as evidenced by recent studies [15–17]. This evidence concerns the gene SLC6A14 and cystic fibrosis.